- Home
- PLX vs OXSQ Comparison
PLX vs OXSQ Comparison
Compare PLX & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- OXSQ
- Stock Information
- Founded
- PLX 1993
- OXSQ 2003
- Country
- PLX Israel
- OXSQ United States
- Employees
- PLX N/A
- OXSQ N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- OXSQ Blank Checks
- Sector
- PLX Health Care
- OXSQ Finance
- Exchange
- PLX Nasdaq
- OXSQ Nasdaq
- Market Cap
- PLX 160.2M
- OXSQ 175.2M
- IPO Year
- PLX 1998
- OXSQ N/A
- Fundamental
- Price
- PLX $2.33
- OXSQ $2.66
- Analyst Decision
- PLX
- OXSQ
- Analyst Count
- PLX 0
- OXSQ 0
- Target Price
- PLX N/A
- OXSQ N/A
- AVG Volume (30 Days)
- PLX 553.9K
- OXSQ 556.5K
- Earning Date
- PLX 03-13-2025
- OXSQ 03-14-2025
- Dividend Yield
- PLX N/A
- OXSQ 15.87%
- EPS Growth
- PLX N/A
- OXSQ N/A
- EPS
- PLX N/A
- OXSQ N/A
- Revenue
- PLX $45,667,000.00
- OXSQ $44,787,853.00
- Revenue This Year
- PLX N/A
- OXSQ N/A
- Revenue Next Year
- PLX $90.00
- OXSQ N/A
- P/E Ratio
- PLX N/A
- OXSQ N/A
- Revenue Growth
- PLX N/A
- OXSQ N/A
- 52 Week Low
- PLX $0.82
- OXSQ $2.40
- 52 Week High
- PLX $2.36
- OXSQ $3.29
- Technical
- Relative Strength Index (RSI)
- PLX 78.72
- OXSQ 57.50
- Support Level
- PLX $2.11
- OXSQ $2.51
- Resistance Level
- PLX $2.36
- OXSQ $2.70
- Average True Range (ATR)
- PLX 0.12
- OXSQ 0.05
- MACD
- PLX 0.00
- OXSQ 0.02
- Stochastic Oscillator
- PLX 94.23
- OXSQ 86.67
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.